Phathom Pharmaceuticals, Inc. Operating Income

Operating Income of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income growth rates and interactive chart. Operating income is the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation, and cost of goods sold (COGS). Operating income–also called income from operations–takes a company's gross income, which is equivalent to total revenue minus COGS, and subtracts all operating expenses. A business's operating expenses are costs incurred from normal operating activities and include items such as office supplies and utilities. Operating income is measured before interest and tax expenses and is a good gauge of a company's operational profitability.


Highlights and Quick Summary

  • Operating Income for the quarter ending June 29, 2021 was $-35.3 Million (a 5.17% increase compared to previous quarter)
  • Year-over-year quarterly Operating Income increased by 7.58%
  • Annual Operating Income for 2020 was $-126 Million (a 18.31% increase from previous year)
  • Annual Operating Income for 2019 was $-106 Million (a 8570.61% increase from previous year)
  • Twelve month Operating Income ending June 29, 2021 was $-154 Million (a 11.02% increase compared to previous quarter)
  • Twelve month trailing Operating Income increased by 73.38% year-over-year
Trailing Operating Income for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-154 Million $-139 Million $-126 Million $-88.9 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income of Phathom Pharmaceuticals, Inc.

Most recent Operating Incomeof PHAT including historical data for past 10 years.

Interactive Chart of Operating Income of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Operating Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-35.32 $-33.58
2020 $-52.44 $-32.83 $-20.02 $-20.38 $-125.67
2019 $-15.69 $-6.28 $-83.01 $-1.23 $-106.22
2018 $-0.27 $-1.23

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.